HARMONY has been named as a winner of the International Society of Pharmacoeconimics and Outcomes Research (ISPOR) prestigious Best New Investigator Award. The award-winning poster, titled ‘A multilevel evidence access framework for innovative technologies specific to haematological malignancies’ (PCV156), was presented by HARMONY Partner NICE (the National Institute for Health and Care Excellence) at ISPOR Europe 2019, Copenhagen, Denmark.
Lead Researcher and Scientific Advisor at NICE, Dr Katy Harrison, presented the poster, which was one of hundreds showcased at ISPOR and one of 18 final winners.
The poster outlines HARMONY’s new framework, which aims to guide evidence generation to support market access for blood cancer drugs across Europe – a common challenge given the jurisdictional differences across countries. The framework uses information on outcomes of previous reimbursement decisions across European countries to assess the likelihood that a drug is approved based on safety, efficacy, cost and economic requirements by a particular health technology assessment (HTA) body. The framework has the potential to change how HTA submissions are prepared and may prove invaluable for improving the likelihood of approval of such submissions.
The framework will be freely accessible once published.
Click here to view the poster >
Click here to view the official ISPOR awards announcement page >
We would like to thank our Partners at NICE, Celgene International, Janssen-Cilag Germany, AEMPS Spain, BfArM Germany, Abbvie and Novartis UK for their exceptional work on this project.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
